Jie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jie Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Ding Wang
Department of Neurosurgery, Hangzhou First People Hospital, Hangzhou, China
2 shared publicationsHaiyang Wang
Department of Neurosurgery, Hangzhou First People Hospital, Hangzhou, China
2 shared publications- Quan Du
Department of Neurosurgery, Hangzhou First People Hospital, Hangzhou, China
2 shared publications - Qian Jin
Affiliated Hangzhou First People's Hospital, School ofMedicine, Westlake University, Operation room; The Fourth School ofClinical Medicine, Zhejiang Chinese Medical University, Hangzhou FirstPeople's Hospital, Operation room
1 shared publication Wenhao Zheng
Department of Neurosurgery, Hangzhou First People Hospital, Hangzhou, China
1 shared publication- Wenhua Yu
Department of Neurosurgery, Hangzhou First People Hospital, Hangzhou, China
1 shared publication
Latest Publications
- 23 October 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (6) , 218
Silymarin attenuates neuroinflammation after subarachnoid hemorrhage by inducing M2 microglial polarization via activation of the JAK1/STAT6 signaling pathway
Neuroinflammation represents a key pathological process in early brain injury (EBI) following subarachnoid hemorrhage (SAH) and contributes significantly to poor outcomes. Silymarin, known for its anti-inflammatory and antioxidant activities, has been shown to exert neuroprotective effects. Nevertheless, the molecular mechanisms underlying these effects remain to be clarified. An in vivo endovascular perforation model and an in vitro hemoglobin-stimulated model were used to investigate the pharmacological effects of silymarin in SAH. Neurological function was assessed using SAH scores and neurobehavioral scores. Neuronal apoptosis was evaluated by TUNEL staining. Neuroinflammation was measured by ELISA or qPCR, and microglial polarization status was determined by assessing CD86 and CD206 expression via Western blotting (WB) or immunofluorescence (IF) staining. Ruxolitinib and AS1517499 were applied to block the JAK1/STAT6 pathway. Silymarin attenuated early brain injury (EBI) after SAH, as indicated by improved neurological scores, reduced neuronal apoptosis, and lower brain water content. In vivo, silymarin treatment was associated with JAK1/STAT6 activation, elevated M2 markers, and decreased pro‑inflammatory cytokines. In vitro, silymarin activated the JAK1/STAT6 pathway, promoted M2 microglial polarization, and suppressed inflammatory cytokine production. In addition, pharmacological blockade of JAK1/STAT6 reversed silymarin’s protective effects, confirming a causal role of this pathway in the cellular context. Our in vitro data demonstrate that silymarin directly stimulates JAK1/STAT6 to drive M2 polarization and anti‑inflammatory responses. In vivo, we observed a correlation between pathway activation and neuroprotective benefits. Together, these findings provide a rationale for further exploring silymarin‑based therapies in SAH.
- 23 October 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (6) , 218
Silymarin attenuates neuroinflammation after subarachnoid hemorrhage by inducing M2 microglial polarization via activation of the JAK1/STAT6 signaling pathway
Neuroinflammation represents a key pathological process in early brain injury (EBI) following subarachnoid hemorrhage (SAH) and contributes significantly to poor outcomes. Silymarin, known for its anti-inflammatory and antioxidant activities, has been shown to exert neuroprotective effects. Nevertheless, the molecular mechanisms underlying these effects remain to be clarified. An in vivo endovascular perforation model and an in vitro hemoglobin-stimulated model were used to investigate the pharmacological effects of silymarin in SAH. Neurological function was assessed using SAH scores and neurobehavioral scores. Neuronal apoptosis was evaluated by TUNEL staining. Neuroinflammation was measured by ELISA or qPCR, and microglial polarization status was determined by assessing CD86 and CD206 expression via Western blotting (WB) or immunofluorescence (IF) staining. Ruxolitinib and AS1517499 were applied to block the JAK1/STAT6 pathway. Silymarin attenuated early brain injury (EBI) after SAH, as indicated by improved neurological scores, reduced neuronal apoptosis, and lower brain water content. In vivo, silymarin treatment was associated with JAK1/STAT6 activation, elevated M2 markers, and decreased pro‑inflammatory cytokines. In vitro, silymarin activated the JAK1/STAT6 pathway, promoted M2 microglial polarization, and suppressed inflammatory cytokine production. In addition, pharmacological blockade of JAK1/STAT6 reversed silymarin’s protective effects, confirming a causal role of this pathway in the cellular context. Our in vitro data demonstrate that silymarin directly stimulates JAK1/STAT6 to drive M2 polarization and anti‑inflammatory responses. In vivo, we observed a correlation between pathway activation and neuroprotective benefits. Together, these findings provide a rationale for further exploring silymarin‑based therapies in SAH.
- Open Access
- 20 April 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2654257
Efficacy analysis of combined nerve combing and decompression for occipital neuralgia based on the classification of neurovascular relationships
This study set occipital pain improvement as the primary endpoint, and overall headache relief, migraine index, medication use and complication rate as secondary endpoints, to evaluate the efficacy and safety of neural combing plus decompression guided by four neurovascular relationship subtypes for drug-resistant occipital neuralgia (ON). We retrospectively reviewed 53 patients with drug-resistant ON who underwent unilateral or bilateral greater occipital nerve (GON) combing and decompression. All had ineffective drug treatment for ≥1 year and follow-up ≥12 months. Efficacy was evaluated by comparing monthly pain days, Visual Analog Scale (VAS), medication use and migraine index pre- and postoperatively. Complications were recorded. Postoperatively, 88.7% (47/53) of patients achieved ≥50% ON improvement, and 67.9% (36/53) had complete pain remission. Monthly chronic pain days fell by 72.6%, attack days by 85.0%. Baseline VAS decreased from 2.6 to 1.0, peak attack VAS from 6.4 to 0.8. Medication use dropped by 70%, with significant reductions in NSAIDs, triptans and opioids (P < 0.01). Only one minor complication occurred, with no severe adverse events. The combined GON combing and decompression technique guided by the four subtypes of neurovascular relationships enables the precise release of nerve compression points while preserving neural structures. It significantly improves pain symptoms and quality of life in patients with drug-resistant ON, offering minimal trauma and fewer complications. Hence, this technique is a safe and valuable minimally invasive therapeutic option for the invasive treatment of drug-resistant ON, which warrants further prospective comparative studies and wider clinical application.
- 20 April 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2654257
Open AccessEfficacy analysis of combined nerve combing and decompression for occipital neuralgia based on the classification of neurovascular relationships
This study set occipital pain improvement as the primary endpoint, and overall headache relief, migraine index, medication use and complication rate as secondary endpoints, to evaluate the efficacy and safety of neural combing plus decompression guided by four neurovascular relationship subtypes for drug-resistant occipital neuralgia (ON). We retrospectively reviewed 53 patients with drug-resistant ON who underwent unilateral or bilateral greater occipital nerve (GON) combing and decompression. All had ineffective drug treatment for ≥1 year and follow-up ≥12 months. Efficacy was evaluated by comparing monthly pain days, Visual Analog Scale (VAS), medication use and migraine index pre- and postoperatively. Complications were recorded. Postoperatively, 88.7% (47/53) of patients achieved ≥50% ON improvement, and 67.9% (36/53) had complete pain remission. Monthly chronic pain days fell by 72.6%, attack days by 85.0%. Baseline VAS decreased from 2.6 to 1.0, peak attack VAS from 6.4 to 0.8. Medication use dropped by 70%, with significant reductions in NSAIDs, triptans and opioids (P < 0.01). Only one minor complication occurred, with no severe adverse events. The combined GON combing and decompression technique guided by the four subtypes of neurovascular relationships enables the precise release of nerve compression points while preserving neural structures. It significantly improves pain symptoms and quality of life in patients with drug-resistant ON, offering minimal trauma and fewer complications. Hence, this technique is a safe and valuable minimally invasive therapeutic option for the invasive treatment of drug-resistant ON, which warrants further prospective comparative studies and wider clinical application.